Determination and Correlation of Anticardiolipin Antibody with High Sensitivity C- reactive Proteins and its Role in Predicting Short Term Outcome in Patients with Acute Coronary Syndrome

Malhotra, AS and Sharma, R and Mehta, J and Kashyap, JR and Gupta, V and Kapoor, N and Sachdev, A (2011) Determination and Correlation of Anticardiolipin Antibody with High Sensitivity C- reactive Proteins and its Role in Predicting Short Term Outcome in Patients with Acute Coronary Syndrome. [Journal (On-line/Unpaginated)]

Full text available as:

PDF - Published Version
Available under License Creative Commons Attribution No Derivatives.



Anticardiolipin antibody (aCL) is considered to be an independent risk factor while high sensitivity C reactive protein (hsCRP) is an established marker for coronary artery disease. This study was conducted to determine levels of aCL antibodies and hsCRP, their correlation and role in predicting recurrence of events in patients presenting with Acute Coronary Syndrome (ACS). Sixty patients admitted with Acute Coronary Syndrome were followed up for 7 days or until discharge. Patients were classified into two groups as those having experienced an ischemic event needing intervention within 7 days (Group I) and other having an event free recovery (Group II). aCL antibody and hsCRP levels were estimated and compared in these two groups. Twenty age and sex matched disease free persons served as controls. The levels of aCL were significantly higher in patients with ACS as compared to the controls (p=0.020). However the levels of aCL in Group I (13.39±9.46 GPL-U/ml) and Group II (13.51±9.93 GPL-U/ml) were not significantly different (p =0.838). The mean hsCRP levels were higher in cases with an event (23.30±10.68 mg/dl) than in cases without an event (20.60±11.45mg/dl) though it was not significant statistically (p=0.389). aCL and CRP were not found to be significantly correlated in causing the recurrence of events(p=0.178). Therefore anticardiolipin antibody is an independent risk factor which could be implicated in the pathogenesis of ACS. However it is not significantly associated with recurrence of short-term events in patients with ACS. Also, aCL antibody does not have significant correlation with hSCRP in causing recurrence of events in the patients of acute coronary syndrome.

Item Type:Journal (On-line/Unpaginated)
Keywords:Acute coronary syndrome; Anticardiolipin antibodies; High sensitivity C -reactive protein; Myocardial infarction; Composite end point
Subjects:JOURNALS > Online Journal of Health and Allied Sciences
ID Code:7823
Deposited By: Kakkilaya Bevinje, Dr. Srinivas
Deposited On:15 Dec 2011 23:59
Last Modified:15 Dec 2011 23:59

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Feinbloom D, Bauer KA. Assessment of Hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005;25:2043-2053.

2. Glueck CJ et al. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol 1999;83:1490-1494.

3. Hamsten A, Bjorkholm M, Norberg et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;1:113-116.

4. Zuckerman E, Toubi E, Shiran A et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med. 1996;171:381-386.

5. Sletnes KE, Smith P, Abdelnoor M et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality reinfarction and non- haemorrhagic stroke. Lancet 1992;339:451-453.

6. Phadke KV, Philips RA, Clarke DTR, et al. Anticardiolipin antibodies in ischemic heart disease: marker or myth? Br Heart J.1993;69:391-394.

7. Varala O, Alftan G, Jauhiainen M et al. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythemetosus. Lancet.1993;341:923-925.

8. Martinuzzo ME, Maclouf J, Carreras LO, et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost. 1993; 70: 667-671.

9. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of antiphospholipid syndrome? J Autoimmune 2000;15(2):163-172.

10. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of literature. Blood 2003;101:1827-1832.

11. Elgharib N, Chi DS, Younis W , Wehbe S, Krishnaswamy G. C-reactive protein as a novel biomarker: reactant can flag atherosclerosis and help predict cardiac events. Postgrad Med 2003;114(6):39-44

12. Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL. High sensitivity C-reactive protein, Lipoprotein associated phosphorlipase A2 and outcome after ischemic stroke. Arch Intern Med. 2006;166:2073-2080. Available at Accessed Apr 14, 2011

13. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(4suppl 5):37S-42S

14. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction –summary article: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol.2002;40:1366-1374.

15. Nasonov EL, Noeva FA, Kovalev VIu, et al. Cardiolipin antibodies in patients with myocardial infarction and unstable angina pectoris. Kardiologiia 1992;32(5):32-34

16. Klemp P, Cooper RC, Strauss FJ, et al. Anti-cardiolipin antibodies in ischemic heart disease. Clin Exp Immunol 1988;74:254-257

17. Sharma S, Malhotra A, Sharma PY et al. Association of anticardiolipin antibodies levels with instent restenosis in patient with coronary artery disease. Indian J Physiol Pharmacol 2008;52(3):288-292

18. Bili A, Moss AJ, Francis CW et al. Anticardiolipin antibodies and recurrent coronary events. Circulation 2000;102:1258-1263.

19. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Eng J Med 1992;326(4):242-250

20. Eber B, Kronberger-Schaffer E, Brussee H, Klima G, et al. Anticardiolipin antibodies are no marker for survived myocardial infarction. Klin Wochenschr. 1990:68:594-596.

21. Gurlek A, Ozdol C, Pamir G, Dincer J, Tutkak H, Oral D. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome. Int Heart J Jul 2005;46:631-638.

22. Moss MD, Robert E, Goldstein MD et al. Thrombogenic factors and recurrent coronary events. Circulation. 1999;99:2517-2522.

23. Torres JL, Ridker PM. Clinical use of high-sensitivity c-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003;18:471-478.

24. Jialal I, Devraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6-11.

25. Perason TA, Mensah GA, Hong Y, smith SC Jr. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: overview. Circulation 2004;110:e543-544

26. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention [review]. Circulation. 2003;107:363-369.


Repository Staff Only: item control page